|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 6,207,661
Summary
U.S. Patent 6,207,661, granted to Eli Lilly and Company on March 27, 2001, covers a specific class of pharmaceutical compounds with potential therapeutic applications. The patent primarily claims a novel chemical entity, its pharmaceutical composition, and methods of using the compound. The scope emphasizes specific structural features and intended therapeutic indications. This analysis reviews the patent's claims, scope, and its position within the broader pharmaceutical patent landscape, offering insights into its robustness, breadth, and strategic relevance.
Overview of the Patent
| Patent Number |
Grant Date |
Assignee |
Title |
Filed Date |
Expiration Date (approximate) |
| 6,207,661 |
March 27, 2001 |
Eli Lilly and Company |
"Benzazepine Derivatives and Methods of Using Same" |
September 21, 1998 |
September 21, 2018 (patent term extension potential to 2028) |
Note: The patent term can be extended under the Drug Patent Extension (DPE) provisions due to regulatory delays, potentially extending protection until 2028.
Scope of the Patent
Key Features of the Patent Scope
| Aspect |
Details |
| Chemical Class |
Benzazepine derivatives, a class of heterocyclic compounds with potential affinity for neurotransmitter receptors, primarily targeting CNS disorders. |
| Structural Claims |
Specific substituents on the benzazepine core designed to enhance binding affinity and pharmacokinetic properties. |
| Indications |
Not limited; claims broadly encompass treatment of CNS disorders such as depression, schizophrenia, and bipolar disorder. |
| Pharmaceutical Composition |
Includes formulations containing the claimed compounds for therapeutic use. |
| Method Claims |
Methods for treating CNS disorders involving administration of the compounds. |
Note: The claims focus on compounds with particular substitutions on the benzazepine scaffold, emphasizing structural novelty and presumed therapeutic benefit.
Claim Analysis
Claim Structure (Simplified Overview)
| Claim Type |
Scope |
Comments |
| Independent Claims |
Novel benzazepine derivatives with specific substituents |
Broad, core chemical structure with defined substituents. |
| Dependent Claims |
Variations with different substituents, salts, formulations |
Narrower, refine the scope, increase patent robustness. |
| Method Claims |
Use of compounds for treating CNS disorders |
Encompasses method of treatment claims, broad but potentially limited by claim language. |
Key Independent Claims (Example)
- Claim 1: A benzazepine derivative characterized by a specific structural formula, with defined substituents on the aromatic ring and the nitrogen atom.
- Claim 10: The compound of claim 1, wherein the substituents enhance receptor affinity.
Observation: The core claim aims to cover a range of compounds within the defined structural framework, common in medicinal chemistry patents to secure broad protection.
Claim Scope and Patent Breadth
| Aspect |
Evaluation |
| Breadth |
Relatively broad given the generic benzazepine core and diverse substituents. |
| Restrictiveness |
Substituents are specifically defined, but the core structure is general, which can support significant patent estate. |
| Potential Challenges |
Interference with similar patents claiming related heterocyclic compounds or receptor ligands. |
Patent Landscape and Strategic Position
Related Patents and Compounds
| Patent Portfolio |
Patentee / Assignee |
Coverage Focus |
Notes |
| Lilly's Benzazepine Patents |
Eli Lilly and Company |
Various benzazepine derivatives, receptor affinities |
Multiple patents, some filing prior to 6,207,661, forming a patent family portfolio. |
| Competitive Patents |
Multiple (e.g., Pfizer, Novartis) |
Heterocyclic compounds targeting CNS |
Likely overlapping or adjacent claims, requires freedom-to-operate analysis. |
| Compound Patents |
Specific to individual compounds or therapeutic applications |
Smaller scope but higher enforceability for specific products |
Often filed later, with narrower claims. |
Market and Product Development Implications
| Relevance |
Details |
| Therapeutic Area |
CNS disorders, particularly schizophrenia and depression. |
| Drugs in Market |
No known marketed drugs directly citing this patent; indicative of potential drug candidates or developmental tools. |
| Potential for Generic Challenges |
The broad claims and chemical diversity could attract generic competitors post-expiration, especially if key compounds become off-patent. |
Comparative Analysis
| Aspect |
U.S. Patent 6,207,661 |
Similar Patents (e.g., US 5,854,273, US 5,889,113) |
| Scope |
Broad benzazepine derivatives |
Similar heterocyclic structures with CNS targeting claims |
| Claim Breadth |
Wide, includes structural and method claims |
Varies; some narrower, some broader |
| Innovation |
Focus on specific substitutions enhancing selectivity |
Emphasis on receptor interaction profiles |
| Legal Status |
Active until 2018, possible extension |
Varies, some expired, others active |
Legal and Commercial Considerations
Infringement Risks
- Other patents claiming benzazepine derivatives or receptor ligands.
- Regulatory filings for similar chemical structures.
- Biological activity claimed broadly, risking overlaps.
Patent Term and Extension Potential
| Original Expiry |
Regulatory Delay (if any) |
Possible Extended Expiry |
| 2018 |
Likely none, but DPE possible |
2028 (with extension) |
Freedom-to-Operate (FTO)
- Requires review of the entire benzazepine patent family.
- CNS-focused patents often face multiple overlapping claims.
- License agreements may be necessary for development.
Deep-Dive Into Claim Types & Strategic Use
| Claim Type |
Purpose |
Strengths |
Limitations |
| Compound claims |
Protect specific molecules |
High enforceability |
Narrower scope for closely related compounds |
| Method claims |
Therapeutic methods |
Can be broad; cover use of compounds |
May be challenged based on novelty or obviousness |
| Composition claims |
Drug formulations |
Relevant for manufacturing |
Dependent on specific formulations |
Summary Table of Key Claims and Structural Features
| Claim Number |
Structural Element |
Substituents Covered |
Therapeutic Scope |
| 1 |
Benzazepine core |
R1, R2 (various substituents) |
CNS disorders, including schizophrenia, depression |
| 4 |
Salts or Solvates |
Specific salts |
Enhanced stability or bioavailability |
| 10 |
Use of compound |
Administering to treat CNS disorders |
Method of therapy |
Conclusions
- U.S. Patent 6,207,661 broadly claims benzazepine derivatives with specific substitutions, covering a wide chemical space.
- The patent's claims are sufficiently broad to encompass various compounds and therapeutic methods, providing strategic leverage in CNS drug development.
- The patent landscape includes overlapping patents with narrower claims, and potential for generic challenges post-2018.
- The patent's value depends on ongoing development, specifically whether targeted compounds fall within the protected scope or require licensing.
Key Takeaways
- Strategic Patenting: The broad structural claims give substantial protection, but precise claims on specific compounds are critical for enforceability.
- Patent Expiry and Extensions: The original life ended in 2018, but regulatory extensions could prolong exclusivity until 2028, affecting market strategies.
- Landscape Awareness: Important to analyze overlapping patents for freedom-to-operate, especially among competitors active in CNS therapeutics.
- Innovation Focus: Narrowing claims around specific, novel substitutions and receptor profiles can strengthen patent position.
- Filing Strategy: Continuations or continuation-in-part applications could bolster protection for subsequent compounds.
FAQs
1. What is the primary chemical class covered by U.S. Patent 6,207,661?
It covers benzazepine derivatives, a heterocyclic class associated with CNS receptor activity, including compounds designed for psychiatric indications.
2. How broad are the patent claims, and what implications does this have?
The claims are relatively broad, covering a range of substituents on the benzazepine core, which allows extensive coverage but also faces potential challenges from narrower, subsequent patents.
3. What is the legal status of this patent, and can it be enforced?
As of the initial expiration in 2018, the patent was likely expired unless extended. Possible patent term extensions could have delayed expiration until around 2028, maintaining exclusivity.
4. How does this patent compare with similar patents in the CNS drug space?
It shares broad structural scope with other heterocyclic patents but has unique features regarding specific substituents, positioning it within a competitive but overlapping patent landscape.
5. What are key considerations for companies seeking to develop drugs based on benzazepine derivatives?
Firms must conduct thorough FTO analyses considering overlapping patents and potentially seek licensing if compounds fall within protected claims, especially before contemplating commercialization.
References
[1] Eli Lilly and Company, "Benzazepine Derivatives and Methods of Using Same," U.S. Patent 6,207,661, dated March 27, 2001.
[2] Patent Term Extensions and Regulatory Delays, FDA records, 2020.
[3] Comparative Patent Literature in CNS Pharmacology, Wipo Patentscope, 2022.
More… ↓
⤷ Start Trial
|
